Valuation Metrics Indicate Elevated Pricing
As of 26 Nov 2025, Krishna Institu.'s valuation grade shifted from expensive to very expensive. The company’s price-to-earnings (PE) ratio stands at an elevated 83.7, significantly higher than the broader hospital industry average. This high PE ratio suggests that investors are paying a substantial premium for each unit of earnings, reflecting expectations of strong future growth or market dominance.
Further, the price-to-book (P/B) ratio is above 12, indicating that the stock is valued at more than twelve times its net asset value. Such a multiple is considerably steep compared to typical industry standards, signalling that the market anticipates sustained profitability and asset utilisation.
The enterprise value to EBITDA (EV/EBITDA) ratio of nearly 39 also underscores the expensive nature of the stock. This metric, which adjusts for debt and cash, is a key indicator of operational profitability relative to valuation. Krishna Institu.’s EV/EBITDA is among the highest in its peer group, suggesting limited margin of safety for new investors at current prices.
Comparative Analysis with Peers
When benchmarked against notable hospital sector peers, Krishna Institu. ranks among the most expensive. For instance, Max Healthcare and Fortis Healthcare also trade at very expensive valuations but with slightly lower PE and EV/EBITDA multiples. Apollo Hospitals, by contrast, is considered attractive with a more moderate PE ratio and EV/EBITDA, offering a comparatively better valuation proposition.
Peers such as Narayana Hrudaya and Aster DM Healthcare show expensive valuations but still fall short of Krishna Institu.’s premium pricing. This disparity highlights the market’s high expectations for Krishna Institu., which may be driven by its growth trajectory or perceived competitive advantages.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Financial Performance and Returns
Krishna Institu. has delivered robust returns over the medium to long term. Its three-year stock return of 132.4% significantly outpaces the Sensex’s 37.4% gain over the same period. Year-to-date and one-year returns also comfortably exceed benchmark indices, reflecting strong investor confidence and operational execution.
However, the company’s return on capital employed (ROCE) and return on equity (ROE) stand at moderate levels of 10.6% and 14.4% respectively. While these figures indicate reasonable profitability, they do not fully justify the extremely high valuation multiples, especially when compared to peers with similar or better returns at lower prices.
Notably, Krishna Institu. does not currently offer a dividend yield, which may deter income-focused investors seeking regular cash returns.
Price Movement and Market Sentiment
The stock’s current price of ₹684.75 is near its 52-week high of ₹798, indicating strong recent momentum. Daily trading ranges show moderate volatility, with the latest session’s high and low at ₹685.10 and ₹670.40 respectively. Despite a slight pullback over the past month, the stock remains resilient relative to the broader market.
Such price action suggests that while the market remains optimistic about Krishna Institu.’s prospects, the elevated valuation leaves limited room for error. Any slowdown in growth or adverse sector developments could prompt a re-rating.
Holding Krishna Institu. from Hospital? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Conclusion: Overvalued with Growth Premium
In summary, Krishna Institu. is currently overvalued relative to its hospital sector peers based on key valuation metrics such as PE, P/B, and EV/EBITDA ratios. The company’s premium pricing reflects strong investor expectations for future growth and market leadership, supported by impressive historical returns.
However, moderate profitability ratios and the absence of dividend yield suggest that the valuation premium may be stretched. Investors should weigh the potential for continued growth against the risk of valuation correction, especially given the stock’s proximity to its 52-week highs.
For those seeking exposure to the hospital sector, it may be prudent to consider alternative stocks with more attractive valuations or better risk-reward profiles. Careful portfolio positioning and ongoing monitoring of sector dynamics will be essential to navigate this expensive market segment effectively.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
